In this equity report, analyst Gustav Lill takes a deep-dive into Zenicor Medical Systems. Zenicor is a Swedish medtech company disrupting how we discover arrhythmia with a 3-5 times better efficiency than conventional methods. A recent change to a more favourable business model will drive the top-line growth with a CAGR of 20,7% 2020-2022, which indicates a share price upside of 67,0% until 2021E.

Investment highlights:

  • Strong scientific support by over 30 independently published scientific studies and 6 doctoral dissertations.
  • A new business model directly correlated with number of patients using it and matches health centres compensation model.

To get the analyst’s full view, please see the report below: